Chunghyuldan activates NOS mRNA expression and suppresses VCAM-1 mRNA expression in human endothelial cells

Seong Uk Park, Woo Sang Jung, Sang Kwan Moon, Chang Nam Ko, Ki Ho Cho, Young Suk Kim, Hyung Sup Bae, Sung-Gil Chi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Chunghyuldan (CHD), a combinatorial drug that has antihyperlipidemic and anti-inflammatory activities, has been shown to improve arterial stiffness and inhibit stroke recurrence in clinical study. To understand the molecular basis of CHD's clinical effects, we explored its effect on cell proliferation and expression of nitric oxide synthase (NOS) and vascular cell adhesion molecule (VCAM-1) in human umbilical vein endothelial cells (HUVECs). Cell number counting and [3H]thymidine incorporation assay demonstrated that nontoxic doses of CHD have an inhibitory effect on DNA synthesis and suppress cell cycle progression of HUVECs. CHD treatment led to a marked induction of NO production through up-regulation of NOS mRNA expression in a dose- and time-dependent manner, whereas it suppressed VCAM-1 expression. CHD inhibition of VCAM-1 expression was totally blocked by pretreatment with the NO synthesis inhibitor L-NMMA, whereas pretreatment with the NO donor DETA-NO further decreased VCAM-1 level in CHD-treated HUVECs, indicating that VCAM-1 regulation by CHD is mediated through increased NO synthesis by CHD. In addition, TNF-α-mediated VCAM-1 activation was substantially impeded by CHD treatment. Collectively, our data suggest that anti-inflammatory or anti-hyperlipidemic effects of CHD might be associated with its ability to activate NO production and suppress VCAM-1 expression in human endothelial cells.

Original languageEnglish
Pages (from-to)1101-1108
Number of pages8
JournalCanadian Journal of Physiology and Pharmacology
Volume83
Issue number12
DOIs
Publication statusPublished - 2005 Dec 1

Fingerprint

Vascular Cell Adhesion Molecule-1
Nitric Oxide Synthase
Endothelial Cells
Messenger RNA
Human Umbilical Vein Endothelial Cells
Anti-Inflammatory Agents
Hypolipidemic Agents
Chunghyuldan
omega-N-Methylarginine
Vascular Stiffness
Thymidine
Cell Cycle
Up-Regulation
Cell Count
Stroke
Cell Proliferation
Recurrence
DNA

Keywords

  • Chunghyuldan
  • Human umbilical vein endothelial cell
  • Nitric oxide synthase
  • Vascular cell adhesion molecule-1

ASJC Scopus subject areas

  • Physiology
  • Pharmacology

Cite this

Chunghyuldan activates NOS mRNA expression and suppresses VCAM-1 mRNA expression in human endothelial cells. / Park, Seong Uk; Jung, Woo Sang; Moon, Sang Kwan; Ko, Chang Nam; Cho, Ki Ho; Kim, Young Suk; Bae, Hyung Sup; Chi, Sung-Gil.

In: Canadian Journal of Physiology and Pharmacology, Vol. 83, No. 12, 01.12.2005, p. 1101-1108.

Research output: Contribution to journalArticle

Park, Seong Uk ; Jung, Woo Sang ; Moon, Sang Kwan ; Ko, Chang Nam ; Cho, Ki Ho ; Kim, Young Suk ; Bae, Hyung Sup ; Chi, Sung-Gil. / Chunghyuldan activates NOS mRNA expression and suppresses VCAM-1 mRNA expression in human endothelial cells. In: Canadian Journal of Physiology and Pharmacology. 2005 ; Vol. 83, No. 12. pp. 1101-1108.
@article{7f700f9a5cb94a3097f00cc12fcdebbb,
title = "Chunghyuldan activates NOS mRNA expression and suppresses VCAM-1 mRNA expression in human endothelial cells",
abstract = "Chunghyuldan (CHD), a combinatorial drug that has antihyperlipidemic and anti-inflammatory activities, has been shown to improve arterial stiffness and inhibit stroke recurrence in clinical study. To understand the molecular basis of CHD's clinical effects, we explored its effect on cell proliferation and expression of nitric oxide synthase (NOS) and vascular cell adhesion molecule (VCAM-1) in human umbilical vein endothelial cells (HUVECs). Cell number counting and [3H]thymidine incorporation assay demonstrated that nontoxic doses of CHD have an inhibitory effect on DNA synthesis and suppress cell cycle progression of HUVECs. CHD treatment led to a marked induction of NO production through up-regulation of NOS mRNA expression in a dose- and time-dependent manner, whereas it suppressed VCAM-1 expression. CHD inhibition of VCAM-1 expression was totally blocked by pretreatment with the NO synthesis inhibitor L-NMMA, whereas pretreatment with the NO donor DETA-NO further decreased VCAM-1 level in CHD-treated HUVECs, indicating that VCAM-1 regulation by CHD is mediated through increased NO synthesis by CHD. In addition, TNF-α-mediated VCAM-1 activation was substantially impeded by CHD treatment. Collectively, our data suggest that anti-inflammatory or anti-hyperlipidemic effects of CHD might be associated with its ability to activate NO production and suppress VCAM-1 expression in human endothelial cells.",
keywords = "Chunghyuldan, Human umbilical vein endothelial cell, Nitric oxide synthase, Vascular cell adhesion molecule-1",
author = "Park, {Seong Uk} and Jung, {Woo Sang} and Moon, {Sang Kwan} and Ko, {Chang Nam} and Cho, {Ki Ho} and Kim, {Young Suk} and Bae, {Hyung Sup} and Sung-Gil Chi",
year = "2005",
month = "12",
day = "1",
doi = "10.1139/y05-106",
language = "English",
volume = "83",
pages = "1101--1108",
journal = "Canadian Journal of Physiology and Pharmacology",
issn = "0008-4212",
publisher = "National Research Council of Canada",
number = "12",

}

TY - JOUR

T1 - Chunghyuldan activates NOS mRNA expression and suppresses VCAM-1 mRNA expression in human endothelial cells

AU - Park, Seong Uk

AU - Jung, Woo Sang

AU - Moon, Sang Kwan

AU - Ko, Chang Nam

AU - Cho, Ki Ho

AU - Kim, Young Suk

AU - Bae, Hyung Sup

AU - Chi, Sung-Gil

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Chunghyuldan (CHD), a combinatorial drug that has antihyperlipidemic and anti-inflammatory activities, has been shown to improve arterial stiffness and inhibit stroke recurrence in clinical study. To understand the molecular basis of CHD's clinical effects, we explored its effect on cell proliferation and expression of nitric oxide synthase (NOS) and vascular cell adhesion molecule (VCAM-1) in human umbilical vein endothelial cells (HUVECs). Cell number counting and [3H]thymidine incorporation assay demonstrated that nontoxic doses of CHD have an inhibitory effect on DNA synthesis and suppress cell cycle progression of HUVECs. CHD treatment led to a marked induction of NO production through up-regulation of NOS mRNA expression in a dose- and time-dependent manner, whereas it suppressed VCAM-1 expression. CHD inhibition of VCAM-1 expression was totally blocked by pretreatment with the NO synthesis inhibitor L-NMMA, whereas pretreatment with the NO donor DETA-NO further decreased VCAM-1 level in CHD-treated HUVECs, indicating that VCAM-1 regulation by CHD is mediated through increased NO synthesis by CHD. In addition, TNF-α-mediated VCAM-1 activation was substantially impeded by CHD treatment. Collectively, our data suggest that anti-inflammatory or anti-hyperlipidemic effects of CHD might be associated with its ability to activate NO production and suppress VCAM-1 expression in human endothelial cells.

AB - Chunghyuldan (CHD), a combinatorial drug that has antihyperlipidemic and anti-inflammatory activities, has been shown to improve arterial stiffness and inhibit stroke recurrence in clinical study. To understand the molecular basis of CHD's clinical effects, we explored its effect on cell proliferation and expression of nitric oxide synthase (NOS) and vascular cell adhesion molecule (VCAM-1) in human umbilical vein endothelial cells (HUVECs). Cell number counting and [3H]thymidine incorporation assay demonstrated that nontoxic doses of CHD have an inhibitory effect on DNA synthesis and suppress cell cycle progression of HUVECs. CHD treatment led to a marked induction of NO production through up-regulation of NOS mRNA expression in a dose- and time-dependent manner, whereas it suppressed VCAM-1 expression. CHD inhibition of VCAM-1 expression was totally blocked by pretreatment with the NO synthesis inhibitor L-NMMA, whereas pretreatment with the NO donor DETA-NO further decreased VCAM-1 level in CHD-treated HUVECs, indicating that VCAM-1 regulation by CHD is mediated through increased NO synthesis by CHD. In addition, TNF-α-mediated VCAM-1 activation was substantially impeded by CHD treatment. Collectively, our data suggest that anti-inflammatory or anti-hyperlipidemic effects of CHD might be associated with its ability to activate NO production and suppress VCAM-1 expression in human endothelial cells.

KW - Chunghyuldan

KW - Human umbilical vein endothelial cell

KW - Nitric oxide synthase

KW - Vascular cell adhesion molecule-1

UR - http://www.scopus.com/inward/record.url?scp=33646011257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646011257&partnerID=8YFLogxK

U2 - 10.1139/y05-106

DO - 10.1139/y05-106

M3 - Article

C2 - 16462909

AN - SCOPUS:33646011257

VL - 83

SP - 1101

EP - 1108

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

SN - 0008-4212

IS - 12

ER -